X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs STERLING BIOTECH - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. STERLING BIOTECH WOCKHARDT LTD./
STERLING BIOTECH
 
P/E (TTM) x -18.2 -0.4 - View Chart
P/BV x 1.9 0.0 13,574.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 WOCKHARDT LTD.   STERLING BIOTECH
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
STERLING BIOTECH
Dec-13
WOCKHARDT LTD./
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,01211 9,638.1%   
Low Rs5323 15,632.4%   
Sales per share (Unadj.) Rs355.926.8 1,327.5%  
Earnings per share (Unadj.) Rs-60.3-15.0 403.0%  
Cash flow per share (Unadj.) Rs-46.8-5.5 856.0%  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.854.9 469.8%  
Shares outstanding (eoy) m110.63267.87 41.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.20.3 836.5%   
Avg P/E ratio x-12.8-0.5 2,755.4%  
P/CF ratio (eoy) x-16.5-1.3 1,297.2%  
Price / Book Value ratio x3.00.1 2,363.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,3791,862 4,586.1%   
No. of employees `0006.31.4 461.9%   
Total wages/salary Rs m9,371547 1,713.7%   
Avg. sales/employee Rs Th6,295.05,303.3 118.7%   
Avg. wages/employee Rs Th1,498.3403.8 371.0%   
Avg. net profit/employee Rs Th-1,066.3-2,959.0 36.0%   
INCOME DATA
Net Sales Rs m39,3697,181 548.3%  
Other income Rs m1,20243 2,822.3%   
Total revenues Rs m40,5717,223 561.7%   
Gross profit Rs m18947 1.9%  
Depreciation Rs m1,4952,543 58.8%   
Interest Rs m2,5554,377 58.4%   
Profit before tax Rs m-2,830-5,931 47.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m257-1,924 -13.4%   
Profit after tax Rs m-6,669-4,007 166.4%  
Gross profit margin %013.2 0.4%  
Effective tax rate %-9.132.4 -28.0%   
Net profit margin %-16.9-55.8 30.4%  
BALANCE SHEET DATA
Current assets Rs m33,79614,335 235.8%   
Current liabilities Rs m26,91749,809 54.0%   
Net working cap to sales %17.5-494.0 -3.5%  
Current ratio x1.30.3 436.3%  
Inventory Days Days79403 19.7%  
Debtors Days Days89171 52.3%  
Net fixed assets Rs m39,66455,432 71.6%   
Share capital Rs m553268 206.5%   
"Free" reserves Rs m27,96813,935 200.7%   
Net worth Rs m28,52214,701 194.0%   
Long term debt Rs m21,7319,478 229.3%   
Total assets Rs m81,62073,988 110.3%  
Interest coverage x-0.1-0.4 30.3%   
Debt to equity ratio x0.80.6 118.2%  
Sales to assets ratio x0.50.1 497.0%   
Return on assets %-5.00.5 -1,006.2%  
Return on equity %-23.4-27.3 85.8%  
Return on capital %-7.7-6.4 119.4%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m9,8071,860 527.3%   
Fx outflow Rs m1,78925 7,186.0%   
Net fx Rs m8,0191,835 437.0%   
CASH FLOW
From Operations Rs m6841,719 39.8%  
From Investments Rs m6,302-3,148 -200.2%  
From Financial Activity Rs m-7,6951,426 -539.6%  
Net Cashflow Rs m-664-3 19,529.4%  

Share Holding

Indian Promoters % 74.5 33.9 219.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 0.0 -  
FIIs % 7.7 9.9 77.8%  
ADR/GDR % 0.1 16.9 0.6%  
Free float % 15.4 39.3 39.2%  
Shareholders   67,757 21,482 315.4%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   ALKEM LABORATORIES  PLETHICO PHARMA  FDC LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Healthcare and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued to trade near the dotted line during closing hours and ended the day marginally higher. Gains were largely seen in the healthcare sector .

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

Follow a Super Investor Like This to Multiply Your Wealth(The 5 Minute Wrapup)

Jan 4, 2019

Following a super investor can certainly help build a portfolio and create wealth in the long term.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

HDFC Bank Still Going Strong(Chart Of The Day)

Jan 4, 2019

The stock of HDFC Bank has continued to reward shareholders.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Jan 17, 2019 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - ALEMBIC PHARMA COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS